121 related articles for article (PubMed ID: 10730938)
1. Apoptotic and proliferation indexes in canine lymphoma.
Phillips BS; Kass PH; Naydan DK; Winthrop MD; Griffey SM; Madewell BR
J Vet Diagn Invest; 2000 Mar; 12(2):111-7. PubMed ID: 10730938
[TBL] [Abstract][Full Text] [Related]
2. Immunohistochemical detection of Ki-67 and PCNA in canine mammary tumors: relationship to clinical and pathologic variables.
Peña LL; Nieto AI; Pérez-Alenza D; Cuesta P; Castaño M
J Vet Diagn Invest; 1998 Jul; 10(3):237-46. PubMed ID: 9683072
[TBL] [Abstract][Full Text] [Related]
3. Assessment of potential doubling time (Tpot), argyrophilic nucleolar organizer regions (AgNOR), and proliferating cell nuclear antigen (PCNA) as predictors of therapy response in canine non-Hodgkin's lymphoma.
Vail DM; Kisseberth WC; Obradovich JE; Moore FM; London CA; MacEwen EG; Ritter MA
Exp Hematol; 1996 Jun; 24(7):807-15. PubMed ID: 8647231
[TBL] [Abstract][Full Text] [Related]
4. Prognostic factors for treated canine malignant lymphoma.
Kiupel M; Teske E; Bostock D
Vet Pathol; 1999 Jul; 36(4):292-300. PubMed ID: 10421095
[TBL] [Abstract][Full Text] [Related]
5. Canine lymphomas: association of classification type, disease stage, tumor subtype, mitotic rate, and treatment with survival.
Valli VE; Kass PH; San Myint M; Scott F
Vet Pathol; 2013 Sep; 50(5):738-48. PubMed ID: 23444036
[TBL] [Abstract][Full Text] [Related]
6. Validation of the use of proliferation markers in canine neoplastic and non-neoplastic tissues: comparison of KI-67 and proliferating cell nuclear antigen (PCNA) expression versus in vivo bromodeoxyuridine labelling by immunohistochemistry.
Zacchetti A; van Garderen E; Teske E; Nederbragt H; Dierendonck JH; Rutteman GR
APMIS; 2003 Mar; 111(3):430-8. PubMed ID: 12752223
[TBL] [Abstract][Full Text] [Related]
7. Immunocytochemical study of Ki-67 as a prognostic marker in canine mammary neoplasia.
Zuccari DA; Santana AE; Cury PM; Cordeiro JA
Vet Clin Pathol; 2004; 33(1):23-8. PubMed ID: 15048623
[TBL] [Abstract][Full Text] [Related]
8. Characterization of the proliferation state in canine mammary tumors by the standardized AgNOR method with postfixation and immunohistologic detection of Ki-67 and PCNA.
Löhr CV; Teifke JP; Failing K; Weiss E
Vet Pathol; 1997 May; 34(3):212-21. PubMed ID: 9163877
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of prognostic factors and sequential combination chemotherapy with doxorubicin for canine lymphoma.
Keller ET; MacEwen EG; Rosenthal RC; Helfand SC; Fox LE
J Vet Intern Med; 1993; 7(5):289-95. PubMed ID: 8263847
[TBL] [Abstract][Full Text] [Related]
10. Prognostic significance of Ki67 evaluated by flow cytometry in dogs with high-grade B-cell lymphoma.
Poggi A; Miniscalco B; Morello E; Gattino F; Delaude A; Ferrero Poschetto L; Aresu L; Gelain ME; Martini V; Comazzi S; Riondato F
Vet Comp Oncol; 2017 Jun; 15(2):431-440. PubMed ID: 26792094
[TBL] [Abstract][Full Text] [Related]
11. The effect of budesonide on the expression of Ki-67 and PCNA and the apoptotic index in dogs with inflammatory bowel disease.
Szweda M; Rychlik A; Nowicki M; Kaczmar E
Pol J Vet Sci; 2017 Dec; 20(4):743-750. PubMed ID: 29611642
[TBL] [Abstract][Full Text] [Related]
12. Association of argyrophilic nucleolar organizing regions, Ki-67, and proliferating cell nuclear antigen scores with histologic grade and survival in dogs with soft tissue sarcomas: 60 cases (1996-2002).
Ettinger SN; Scase TJ; Oberthaler KT; Craft DM; McKnight JA; Leibman NF; Charney SC; Bergman PJ
J Am Vet Med Assoc; 2006 Apr; 228(7):1053-62. PubMed ID: 16579784
[TBL] [Abstract][Full Text] [Related]
13. Variation of apoptotic and proliferative activity among lymphoma subtypes in dogs: A flow cytometric study.
Riondato F; Martini V; Melega M; Poggi A; Miniscalco B
Res Vet Sci; 2021 Mar; 135():324-328. PubMed ID: 33779558
[TBL] [Abstract][Full Text] [Related]
14. Growth fractions in canine non-Hodgkin's lymphomas as determined in situ by the expression of the Ki-67 antigen.
Fournel-Fleury C; Magnol JP; Chabanne L; Ghernati I; Marchal T; Bonnefond C; Bryon PA; Felman P
J Comp Pathol; 1997 Jul; 117(1):61-72. PubMed ID: 9263844
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of an actinomycin-D-containing combination chemotherapy protocol with extended maintenance therapy for canine lymphoma.
Siedlecki CT; Kass PH; Jakubiak MJ; Dank G; Lyons J; Kent MS
Can Vet J; 2006 Jan; 47(1):52-9. PubMed ID: 16536229
[TBL] [Abstract][Full Text] [Related]
16. Immunohistochemical detection of proliferating cell nuclear antigen and Ki-67 in mast cell tumors from dogs.
Abadie JJ; Amardeilh MA; Delverdier ME
J Am Vet Med Assoc; 1999 Dec; 215(11):1629-34. PubMed ID: 14567425
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of a multidrug chemotherapy protocol with mitoxantrone based maintenance (CHOP-MA) for the treatment of canine lymphoma.
Daters AT; Mauldin GE; Mauldin GN; Brodsky EM; Post GS
Vet Comp Oncol; 2010 Mar; 8(1):11-22. PubMed ID: 20230577
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of a 6-month chemotherapy protocol with no maintenance therapy for dogs with lymphoma.
Garrett LD; Thamm DH; Chun R; Dudley R; Vail DM
J Vet Intern Med; 2002; 16(6):704-9. PubMed ID: 12465768
[TBL] [Abstract][Full Text] [Related]
19. Utility of a multiple serum biomarker test to monitor remission status and relapse in dogs with lymphoma undergoing treatment with chemotherapy.
Alexandrakis I; Tuli R; Ractliffe SC; Tappin SW; Foale RD; Roos A; Slater KJ
Vet Comp Oncol; 2017 Mar; 15(1):6-17. PubMed ID: 25319380
[TBL] [Abstract][Full Text] [Related]
20. Feline lymphoma (145 cases): proliferation indices, cluster of differentiation 3 immunoreactivity, and their association with prognosis in 90 cats.
Vail DM; Moore AS; Ogilvie GK; Volk LM
J Vet Intern Med; 1998; 12(5):349-54. PubMed ID: 9773411
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
